A three-part first-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of GUB-UCN2 in healthy lean and obese participants and participants with T2D
This is a very early study, called a 'first-in-human' trial, for a new medicine named GUB-UCN2. The main goals are to make sure the medicine is safe and that the body can handle it well. Researchers also want to understand how the medicine moves through the body and what effects it has. The study includes three different groups of people: healthy individuals who are a healthy weight, healthy individuals with obesity, and people who have type 2 diabetes. By studying these different groups, researchers hope to get a good understanding of GUB-UCN2 before it can be tested in larger studies. This kind of research is a crucial first step in developing new treatments for conditions like type 2 diabetes and obesity.
At a glance
What is this study about?
This study is a very first look at a new medicine called GUB-UCN2. Think of it like a brand new recipe – before you serve it at a big dinner party, you first try a small taste to make sure it's safe and you like how it works. That's exactly what this study is doing with GUB-UCN2. It's a 'Phase 1' trial, which means it's the first time this medicine is being given to people.
The main aim of this study is to check for safety. Researchers want to see if the medicine causes any serious side effects and how well people can tolerate it. They will also look at how the body handles the medicine – for example, how much of it reaches the bloodstream and how quickly the body gets rid of it. This helps them understand the right dose to use in the future.
This trial includes three different groups of adults: healthy people who are not overweight, healthy people who have obesity, and people living with type 2 diabetes. By studying these different groups, researchers can see if the medicine acts differently depending on a person's health or body type. Understanding these early details is vital for deciding if GUB-UCN2 has the potential to become a useful new treatment for conditions like type 2 diabetes and obesity in the future.
Key takeaways
- This is an early-stage study checking the safety of a new medicine (GUB-UCN2).
- It's the first time this medicine is being given to people.
- Researchers are looking at healthy people, people with obesity, and people with type 2 diabetes.
- The main goals are to understand how safe the medicine is and what it does in the body.
- It's important for developing future treatments for diabetes and obesity.
Who may be eligible?
To take part in this study, you need to be an adult, aged 18 years or older. The study is open to both men and women. There are no upper age limits, as long as you meet the other health criteria.
The study is looking for three different groups of people: some should be healthy and have a normal weight, some should be healthy but have obesity, and others should have been diagnosed with type 2 diabetes. Specific health checks will be done by the study team to make sure you fit into one of these groups and are generally healthy enough to participate.
It's important to remember that even if you meet these general points, the study team will have more detailed requirements. They will need to check your medical history and do some tests to make sure the study is a safe option for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally healthy, or do you have type 2 diabetes?
- Are you prepared for multiple visits to a clinic?
- Are you able to follow study instructions carefully?
What does participation involve?
If you decide to take part, you would first have a screening visit where doctors would check your health to make sure you're a good fit for the study. If you qualify, you would receive the new medicine, GUB-UCN2, likely as a pill or injection, depending on how it's designed. You would have several visits to the study clinic, possibly including overnight stays, so doctors can closely monitor how your body reacts to the medicine.
During these visits, you can expect to have blood tests, urine tests, and other checks like blood pressure and heart rate measurements. These tests help the researchers understand how the medicine is working in your body and if you're experiencing any side effects. The total length of your participation would be explained during your initial screening, including how many doses you'd receive and how long the follow-up period would be. You'll be given a full schedule if you're eligible.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What does 'first-in-human' mean?
It means this is the very first time this new medicine is being given to people. It's an early safety check.
Will I know if I'm getting the real medicine or a dummy pill?
In this type of study, everyone usually receives the active medicine, but at different doses or at different times, to monitor its effects closely.
How long will I need to be in the study?
The exact duration will depend on which part of the study you join, but it will be fully explained to you before you agree to take part.
Will I get paid for taking part?
Sometimes studies offer payment for your time and travel, but this varies. You should ask the study team directly.
Who is running this study?
Clinical trials are usually sponsored by pharmaceutical companies or research institutions. The study team will provide you with this information.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.